Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM CHLORIDE 10% vs KAON CL-10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving diuretics or other drugs that deplete potassium
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Terminal elimination half-life is approximately 3-5 hours in healthy adults, reflecting rapid equilibration with the total body potassium pool. Clinically, the half-life is not directly applicable due to extensive intracellular distribution; steady-state is achieved within 24-48 hours.
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Potassium is primarily excreted unchanged by the kidneys; metabolism is not significant.
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Primarily renal elimination (>90% as unchanged drug); minor biliary/fecal excretion (<5%). Excretion is via glomerular filtration and tubular reabsorption; potassium excretion is influenced by aldosterone and acid-base status.
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
Potassium is not significantly protein-bound; <5% bound to plasma proteins.
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
Approximately 0.5 L/kg, representing distribution primarily into intracellular fluid (98% of total body potassium is intracellular). Clinical meaning: Low Vd indicates limited distribution to extracellular space; high intracellular uptake requires careful dosing to avoid hyperkalemia.
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
Oral: >90% absorbed via passive diffusion along the gastrointestinal tract. Intravenous: 100% bioavailability.
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
Oral: 1-3 m Eq/kg/day in divided doses, maximum 3 m Eq/kg/day; not recommended for children <1 year.
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
Start at lowest dose (10 m Eq twice daily); monitor renal function and potassium levels; avoid doses exceeding 40 m Eq/day.
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
Warning: Potassium chloride can cause hyperkalemia and cardiac arrest if given too rapidly or in excessive doses. Avoid in patients with severe renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics.
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Monitor serum potassium levels and renal function; avoid high doses or rapid infusion; use with caution in patients with cardiac disease or receiving digitalis; gastrointestinal irritation may occur with oral preparations.
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Severe renal impairment (e.g., anuria, oliguria), untreated Addison's disease, hyperkalemia from any cause, acute dehydration, heat cramps, concurrent use of potassium-sparing diuretics (e.g., amiloride, spironolactone), hypersensitivity to potassium chloride.
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
Avoid salt substitutes and low-sodium products that contain potassium chloride. No specific food restrictions beyond ensuring adequate water intake with each dose to prevent esophageal or gastric irritation.
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been reported. Hypokalemia itself may pose maternal and fetal risks, but the drug does not have intrinsic teratogenic potential.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
Potassium chloride is a normal constituent of breast milk. M/P ratio not applicable as potassium is present endogenously. Supplementation to correct maternal hypokalemia is considered safe during breastfeeding, as potassium levels in milk are tightly regulated and maternal supplementation does not significantly alter infant potassium levels.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
No dose adjustment required for pregnancy. Maternal potassium requirements may increase slightly due to increased plasma volume and renal blood flow, but hypokalemia should be corrected per standard guidelines. Monitor serum potassium to avoid hyperkalemia.
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
Kaon CL-10 is a solid oral dosage form of potassium chloride (KCl) 10 m Eq. Do not split or crush tablets; they must be swallowed whole with a full glass of water to reduce GI irritation. Monitor serum potassium, renal function, and ECG. Use with caution in patients with impaired renal function or those on ACE inhibitors, ARBs, or potassium-sparing diuretics. Rapid IV correction is reserved for severe hypokalemia with ECG changes.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
Take this medication with food and a full glass of water to prevent stomach upset.,Do not crush, chew, or split the tablet; swallow it whole.,Missing a dose: take it as soon as you remember unless almost time for the next dose; do not double up.,Report symptoms of high potassium: muscle weakness, tiredness, numbness/tingling, irregular heartbeat, or confusion.,Do not use salt substitutes or potassium-containing supplements unless directed by your doctor.
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM CHLORIDE 10% vs KAON CL-10, answered by our medical review team.
CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. KAON CL-10 is a Electrolyte Supplement (Potassium) that works by Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM CHLORIDE 10% and KAON CL-10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. The standard adult dose of KAON CL-10 is: Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM CHLORIDE 10% and KAON CL-10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. KAON CL-10 is classified as Category C. Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been report. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.